- Home
- AVR vs FT Comparison
AVR vs FT Comparison
Compare AVR & FT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVR
- FT
- Stock Information
- Founded
- AVR 1999
- FT 1988
- Country
- AVR Australia
- FT United States
- Employees
- AVR N/A
- FT N/A
- Industry
- AVR
- FT Trusts Except Educational Religious and Charitable
- Sector
- AVR
- FT Finance
- Exchange
- AVR NYSE
- FT Nasdaq
- Market Cap
- AVR 162.1M
- FT 192.5M
- IPO Year
- AVR 2024
- FT N/A
- Fundamental
- Price
- AVR $3.36
- FT $7.69
- Analyst Decision
- AVR Strong Buy
- FT
- Analyst Count
- AVR 4
- FT 0
- Target Price
- AVR $16.50
- FT N/A
- AVG Volume (30 Days)
- AVR 315.5K
- FT 63.0K
- Earning Date
- AVR 08-16-2025
- FT 01-01-0001
- Dividend Yield
- AVR N/A
- FT 7.85%
- EPS Growth
- AVR N/A
- FT N/A
- EPS
- AVR N/A
- FT N/A
- Revenue
- AVR $2,493,000.00
- FT N/A
- Revenue This Year
- AVR $25.79
- FT N/A
- Revenue Next Year
- AVR $211.91
- FT N/A
- P/E Ratio
- AVR N/A
- FT N/A
- Revenue Growth
- AVR N/A
- FT N/A
- 52 Week Low
- AVR $2.34
- FT $5.97
- 52 Week High
- AVR $8.79
- FT $7.23
- Technical
- Relative Strength Index (RSI)
- AVR N/A
- FT 55.56
- Support Level
- AVR N/A
- FT $7.43
- Resistance Level
- AVR N/A
- FT $7.53
- Average True Range (ATR)
- AVR 0.00
- FT 0.09
- MACD
- AVR 0.00
- FT 0.00
- Stochastic Oscillator
- AVR 0.00
- FT 61.54
About AVR ANTERIS TECHNOLOGIES GLOBAL CORP
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.